Therefore, we intend to further study the combined treatment of this novel PD-L1-containing MUC1-Vax tumor vaccine with immune checkpoint inhibitors, such as PD-1 mAb to verify whether it can achieve better efficacy. This evidence concerns the gene CD274 and neoplasm.